Journal article · 2022 · Open access

Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial

Rezvan Salehidoost, Golshan Taghipour Boroujeni, Awat Feizi, Ashraf Aminorroaya, Masoud Amini

Scientific Reports, 12(1), 18209 · Published 28 October 2022 · DOI 10.1038/s41598-022-20277-6

Free PDFView at the publisherCite this paper

In brief

“Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial” is a 2022 journal article by Rezvan Salehidoost and 4 co-authors, published in Scientific Reports. OpenAlex counts 25 citations as of 15 November 2026, which puts it in the top 3% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Scientific Reports.

Citations
25
Most cited in
2023 (7)
Field-weighted impact
2.59
References
41
Authors
5

Abstract

To evaluate the effect of magnesium supplementation on insulin resistance and cardiovascular markers in people with prediabetes. A 12 week double-blind placebo-controlled randomized clinical trial was conducted at Isfahan Endocrine and Metabolism Research Center, Iran, on people with prediabetes (n = 86) to compare the effects of magnesium oxide 250 mg/day versus a placebo on anthropometric indices, blood pressure, fasting glucose, insulin, HOMA-IR index, C-reactive protein, uric acid and lipid profile. Both groups had similar distributions of anthropometric and biochemical variables at baseline. Those who received magnesium supplementation had significantly higher levels of HDL-cholesterol compared to the placebo group at the end of the study (49.7 ± 10.9 vs 43.6 ± 7.2 mg/dL, P = 0.003). The mean changes of HOMA-IR index, total cholesterol, LDL-cholesterol, triglyceride, uric acid and C-reactive protein levels as well as anthropometric indices and blood pressure in supplemented and placebo groups did not differ significantly. Magnesium supplementation increased HDL-cholesterol levels in people with prediabetes. However, other cardiometabolic markers were not improved by magnesium supplementation at the above dosage and duration.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Salehidoost, R., Boroujeni, G. T., Feizi, A., Aminorroaya, A., & Amini, M. (2022). Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial. Scientific Reports, 12(1), 18209. https://doi.org/10.1038/s41598-022-20277-6

MLA 9

Salehidoost, Rezvan, et al. “Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.” Scientific Reports, vol. 12, no. 1, 2022, p. 18209. https://doi.org/10.1038/s41598-022-20277-6.

Chicago

Salehidoost, Rezvan, Golshan Taghipour Boroujeni, Awat Feizi, Ashraf Aminorroaya, and Masoud Amini. 2022. “Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.” Scientific Reports 12 (1): 18209. https://doi.org/10.1038/s41598-022-20277-6.

Harvard

Salehidoost, R. et al. (2022) ‘Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial’, Scientific Reports, 12(1), p. 18209. doi:10.1038/s41598-022-20277-6.

IEEE

R. Salehidoost, G. T. Boroujeni, A. Feizi, A. Aminorroaya, and M. Amini, “Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial,” Scientific Reports, vol. 12, no. 1, p. 18209, 2022, doi: 10.1038/s41598-022-20277-6.

BibTeX

@article{salehidoost2022effect,
  title     = {{Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial}},
  author    = {Salehidoost, Rezvan and Boroujeni, Golshan Taghipour and Feizi, Awat and Aminorroaya, Ashraf and Amini, Masoud},
  journal   = {Scientific Reports},
  year      = {2022},
  volume    = {12},
  number    = {1},
  pages     = {18209},
  doi       = {10.1038/s41598-022-20277-6},
  url       = {https://doi.org/10.1038/s41598-022-20277-6}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202377
202466
202555
202677

Its field-weighted citation impact is 2.59: it has been cited 2.59 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Nursing › Nutrition and Dietetics › Magnesium in Health and Disease

  • magnesium supplementation
  • magnesium oxide
  • prediabetes
  • insulin resistance
  • HOMA-IR
  • HDL cholesterol
  • lipid profile
  • C-reactive protein

Work with this paper

Most-cited papers in Nursing

All highly cited Nursing papers

Questions about this paper

How do I cite this paper in APA style?

Salehidoost, R., Boroujeni, G. T., Feizi, A., Aminorroaya, A., & Amini, M. (2022). Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial. Scientific Reports, 12(1), 18209. https://doi.org/10.1038/s41598-022-20277-6

How many times has this paper been cited?

25 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Scientific Reports.

Who wrote this paper?

Rezvan Salehidoost, Golshan Taghipour Boroujeni, Awat Feizi, Ashraf Aminorroaya, Masoud Amini.

What is the DOI of this paper?

10.1038/s41598-022-20277-6. The permanent link is https://doi.org/10.1038/s41598-022-20277-6.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.